ASG Technologies Acquires Mowbly’s Process Mobility Platform
ASG Technologies , a trusted provider of proven solutions for information access, management and control for the world’s top enterprises, today announced that it has acquired Mowbly , an innovative business process mobility platform company. The acquisition extends ASG’s enterprise information management capabilities with the introduction of Business Process Management (BPM) capabilities and enables businesses to construct applications and processes from the perspective of a low-code agile platform with a mobile-first approach.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180307005343/en/
ASG Technologies Acquires Mowbly's Process Mobility Platform (Graphic: Business Wire)
The consumerization of IT has set high expectations among the increasingly mobile workforce. Users now expect immediate access to information, applications and the processes that drive the business regardless of where they are working or what device they are using. IT organizations are looking to work effectively with the business users to seamlessly and securely deliver process-centric content and applications, accessible anytime and anywhere. This business need for real-time data and information marks the beginning of a broader wave of digital transformation underway in enterprises around the globe. Organizations are continually seeking new ways to increase worker productivity and enable business process execution. However, doing so quickly and in line with corporate policies is a major challenge for IT organizations and business leaders alike.
ASG’s acquisition of Mowbly empowers enterprises to embrace this next era of digital transformation. The introduction of BPM capabilities allows users to easily define, manage and automate complex bi-directional processes, which are optimized for ASG solutions and can integrate with third-party systems and span multiple repositories. Users will also benefit from workflow services, giving them the ability to quickly define and execute workflows tied to policies such as document review and approval in ASG Mobius as well as responding to changes to critical data elements in ASG Enterprise Data Intelligence .
The integration with Mowbly also supports agile application development, wherein customers and partners can rapidly build web and mobile applications (including ASG Workspaces widgets) utilizing a low-code approach and visual designer that does not require specialized skills. With the ability to build workflows, processes and applications that leverage the existing content, analytic and delivery capabilities of the current ASG product suites on an open platform, businesses will be able to efficiently and securely connect users with the information and processes they need across PCs, tablets, smartphones and other mobile devices.
“Businesses are under intense pressure to extract actionable insights from their data, automate workflows and processes, and effectively govern the use of information and applications,” said Charles Sansbury, president and chief executive officer of ASG Technologies. “Mowbly’s approach to process mobility demonstrates a unique perspective and capability in the market today, one that addresses the needs of modern businesses to deliver great user experiences while flawlessly managing business processes. For ASG customers and partners, the addition of Mowbly’s process mobility capabilities ensures these two critical elements will always be aligned.”
“Enterprises often spend too much time thinking about solving a business problem in their approach to building a mobile app, instead of the actual need of enabling the business process that is at the core of the initiative,” said Vignesh Swaminathan, chief executive officer of Mowbly. “This principle was a driving force in how we developed our process mobility platform and a vision shared by ASG, which makes it the ideal company to take our capabilities to the next level.”
Today’s news continues the significant momentum ASG Technologies is demonstrating, recently marking nine consecutive quarters of year-over-year license revenue growth amid growing demand for its information management and systems solutions. To learn more about the company, its products and how it is helping enterprises add value to their businesses and succeed as the volume of business data continues to grow, visit www.asg.com .
About ASG Technologies
ASG Technologies brings peace of mind to every enterprise with information access, management and control for our customers. These solutions empower businesses to enhance workforce productivity, gain an accurate and timely understanding of the information that underpins business decisions and address compliance needs with improved visibility of cross-platform data from legacy to leading edge environments. Global Fortune 500 companies trust ASG Technologies to optimize their IT investments. ASG Technologies is a global provider of technology solutions with more than 1,000 people supporting over 3,000 global customers. For more information, visit http://www.asg.com .
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 10:49 | Pressemelding
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha